F
Francisco Marín
Researcher at University of Murcia
Publications - 503
Citations - 13444
Francisco Marín is an academic researcher from University of Murcia. The author has contributed to research in topics: Atrial fibrillation & Medicine. The author has an hindex of 53, co-authored 439 publications receiving 11660 citations. Previous affiliations of Francisco Marín include Carlos III Health Institute & Services Hospital.
Papers
More filters
Journal ArticleDOI
Beneficios y riesgos de los anticoagulantes orales en la fibrilación auricular
Vanessa Roldána,Francisco Marín +1 more
TL;DR: El tratamiento anticoagulante disminuye la tasa de eventos tromboticos, con reducciones de las tasas de ictus y de mortalidad del 64 y el 26% en comparacion with placebo.
Journal ArticleDOI
Comments on the 2018 ESC Guidelines for the Management of Cardiovascular Diseases During Pregnancy
Manuel Jiménez Navarro,Laura Galian-Gay,Pablo Avanzas,Sara Ballesteros,Ana González García,Ernesto González Mesa,Isaac Martínez Bendayán,Antonia Pijuan Domenech,Raquel Prieto,M. Teresa Subirana,Jose L. Bartha,Juan Caro,Juan Luis Delgado,Begoña Manso,Sandra Rosillo,J. Ignacio Zabala,Fernando Alfonso,Borja Ibanez,Fernando Arribas,Gemma Berga Congost,Héctor Bueno,Arturo Evangelista,Ignacio Ferreira-González,Francisco Marín,Leopoldo Pérez de Isla,Antonia Sambola,Rafael Vázquez,Ana Viana-Tejedor +27 more
TL;DR: La incorporacion precoz del enfermo al que se ha realizado una angioplastia con stent a su vida habitual, por ausencia of impedimentos propios de the tecnica, ha permitido incluir mas pronto a estos pacientes en la fase II of the rehabilitacion cardiaca.
Journal ArticleDOI
A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry
María Asunción Esteve-Pastor,José Miguel Rivera-Caravaca,Martín Ruiz-Ortiz,Javier Munoz,Inmaculada Roldán-Rabadán,Debra Otero,Raquel López-Gálvez,Angel Cequier,Vicente Bertomeu-Martínez,Lina Badimon,Manuel Anguita,Gregory Y.H. Lip,Francisco Marín +12 more
TL;DR: The revised evidence in this manuscript and real experience reflects that apixaban and dabigatran show the best efficacy and safety profile, and many guidelines generally do not suggest a specific DOAC choice in clinical practice.
Journal ArticleDOI
Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
Wern Yew Ding,José Miguel Rivera-Caravaca,Elnara Fazio-Eynullayeva,Paula Underhill,Dhiraj Gupta,Francisco Marín,Gregory Y.H. Lip +6 more
TL;DR: In this paper , the effects of left atrial appendage (LAA) occlusion compared to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in patients with atrial fibrillation (AF) remain unknown.
Journal ArticleDOI
Chronic Kidney Disease and Third-Generation P2Y12 Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year.
Antonio Tello-Montoliu,Juan M. Ruiz-Nodar,María Asunción Esteve-Pastor,A Veliz-Martinez,Esteban Orenes-Piñero,Manuel J Macías-Villanego,Teresa Lozano,Luna Carrillo-Alemán,Nuria Vicente-Ibarra,Vicente Pernias-Escrig,Juan Gabriel Martínez-Martínez,José Miguel Rivera-Caravaca,Francisco Marín +12 more
TL;DR: In conclusion, the use of third‐generation P2Y12 inhibitors among non‐CKD patients was associated with better outcomes, and CKD patients receiving third‐ Generation P2y12 inhibitors treatment showed no statistically significant lower mortality and thrombotic events.